Table 2.
Clinicopathologic Features of MDS/CMML Cases
| Feature | XRT (n = 26) |
C/CMT (n = 120) |
P (XRT v C/CMT) | De Novo (n = 103) |
P (XRT v De Novo) | |||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |||
| WHO classification | .8* | .5* | ||||||
| RCUD | 1 | 4 | 5 | 4 | 5 | 5 | ||
| RARS | 3 | 12 | 4 | 3 | 14 | 14 | ||
| RCMD | 11 | 42 | 53 | 44 | 31 | 30 | ||
| RAEB-1 | 5 | 19 | 24 | 20 | 19 | 18 | ||
| RAEB-2 | 5 | 19 | 25 | 21 | 16 | 16 | ||
| MDS-U | 1 | 4 | 5 | 4 | 2 | 2 | ||
| MDS with isolated del (5q) | 0 | 0 | 4 | 4 | ||||
| CMML | 0 | 3 | 3 | 12 | 12 | |||
| Blood counts at presentation | ||||||||
| ANC, × 109/L | .4† | .8† | ||||||
| Median | 2.0 | 1.5 | 2.2 | |||||
| Range | 0-10.3 | 0.3-23.6 | 0-35.5 | |||||
| Hemoglobin, g/dL | .6† | .9† | ||||||
| Median | 9.5 | 9.7 | 9.5 | |||||
| Range | 7.2-12.8 | 5.6-15.3 | 3.7-15.6 | |||||
| Platelets, × 109/L | .3† | .9† | ||||||
| Median | 83 | 68 | 110 | |||||
| Range | 11-331 | 10-355 | 14-524 | |||||
| IPSS score | < .001 (excluding NA category) | .4 (excluding NA category) | ||||||
| Low (0) | 10 | 38 | 4 | 4 | 32 | 31 | ||
| Intermediate-1 (0.5-1) | 9 | 35 | 37 | 36 | 35 | 34 | ||
| Intermediate-2 (1.5-2) | 5 | 19 | 54 | 53 | 27 | 26 | ||
| High (≥ 2.5) | 2 | 8 | 7 | 7 | 2 | 2 | ||
| NA | 0 | 18 | 15 | 7 | 7 | |||
Abbreviations: ANC, absolute neutrophil count; C/CMT, cytotoxic chemotherapy/combined-modality therapy; CMML, chronic myelomonocytic leukemia; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndrome; MDS-U, myelodysplastic syndrome, unclassified; NA, not available; RAEB-1, refractory anemia with excess blasts-1; RAEB-2, refractory anemia with excess blasts-2; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; XRT, external-beam radiation therapy.
*
Fisher's exact test.
†
Pearson's test of medians with continuity correction.